--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About PHVS20260618C25
Pharmaceutical
Pharvaris N.V. was incorporated in the Netherlands on September 30, 2015. They are a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for unmet needs for rare diseases, with an initial focus on angioedema and other bradykinin-mediated diseases. Their first molecule, PHA 121, is a novel small molecule bradykinin B2 receptor antagonist for the treatment of hereditary angioedema, or HAE.
